glp-1 for binge eating Therapy: An Emerging Tool in Psychiatry The therapeutic potential of GLP-1

Escalating Use of GLP-1RAs in Obesity Management GLP-1 agonists, such as semaglutide, received significant attention in 2023 [56]

Can they demonstrate robust raw material control and traceability for critical components

can mimic hematuria Orange Rifampicin, Phenazopyridine, Sulfasalazine, Warfarin Excretion of drug pigments Brown Metronidazole, Levodopa, Nitrofurantoin, Chloroquine, Methyldopa Oxidation of metabolites in urine Black Levodopa, Methyldopa, Phenol poisoning Formation of melanin-like compounds on standing Blue / Green Amitriptyline, Indomethacin, Cimetidine, Propofol, Methylene blue Drug dyes or metabolite excretion Purple Catheter-associated Purple Urine Bag Syndrome (from bacteria metabolizing tryptophan) Seen in catheterized patients with infection Yellow (Intense) Vitamin B-complex (esp

There is reasonable scientific basis to expect that the GLP-1 component will confer similar cardiovascular protection

Abstract Purpose of Review This review summarizes recent advances in the clinical applications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) beyond their established role in glycemic control for type 2 diabetes (T2DM)